FR2686087A1 - Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. - Google Patents

Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. Download PDF

Info

Publication number
FR2686087A1
FR2686087A1 FR9200255A FR9200255A FR2686087A1 FR 2686087 A1 FR2686087 A1 FR 2686087A1 FR 9200255 A FR9200255 A FR 9200255A FR 9200255 A FR9200255 A FR 9200255A FR 2686087 A1 FR2686087 A1 FR 2686087A1
Authority
FR
France
Prior art keywords
protein
antibody
cells
cell
lymphocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR9200255A
Other languages
English (en)
French (fr)
Other versions
FR2686087B1 (https=
Inventor
Boumsell
Bensussan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to FR9200255A priority Critical patent/FR2686087A1/fr
Priority to PCT/FR1993/000025 priority patent/WO1993014125A1/fr
Publication of FR2686087A1 publication Critical patent/FR2686087A1/fr
Application granted granted Critical
Publication of FR2686087B1 publication Critical patent/FR2686087B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR9200255A 1992-01-13 1992-01-13 Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. Granted FR2686087A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR9200255A FR2686087A1 (fr) 1992-01-13 1992-01-13 Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
PCT/FR1993/000025 WO1993014125A1 (fr) 1992-01-13 1993-01-13 Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9200255A FR2686087A1 (fr) 1992-01-13 1992-01-13 Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.

Publications (2)

Publication Number Publication Date
FR2686087A1 true FR2686087A1 (fr) 1993-07-16
FR2686087B1 FR2686087B1 (https=) 1994-04-22

Family

ID=9425559

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9200255A Granted FR2686087A1 (fr) 1992-01-13 1992-01-13 Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.

Country Status (2)

Country Link
FR (1) FR2686087A1 (https=)
WO (1) WO1993014125A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576754B2 (en) * 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
EP1442749A1 (en) * 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
US7919594B2 (en) 2007-02-14 2011-04-05 Vaccinex, Inc. Human anti-CD100 antibodies
JP2011504371A (ja) 2007-11-21 2011-02-10 オレゴン ヘルス アンド サイエンス ユニバーシティー 抗第ｘｉ因子モノクローナル抗体およびその使用方法
CN102317316B (zh) 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
WO2010129917A2 (en) 2009-05-08 2010-11-11 Vaccinex, Inc. Anti-cd100 antibodies and methods for using the same
SG188285A1 (en) 2010-09-02 2013-04-30 Vaccinex Inc Anti-cxcl13 antibodies and methods of using the same
SI2723379T1 (sl) 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Molekule, ki se vežejo ma anti alfa-sinuklein
AU2012322721B2 (en) 2011-10-11 2016-05-05 Vaccinex, Inc. Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability
BR112014010664A2 (pt) 2011-11-02 2017-04-25 Biogen Idec Int Neuroscience Gmbh uso de um anticorpo anti-alfa-sinucleína para diagnosticar um nível elevado de alfa-sinucleína no cérebro
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
NZ629828A (en) 2012-03-02 2017-05-26 Vaccinex Inc Methods for the treatment of b cell-mediated inflammatory diseases
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
CN105408355A (zh) 2013-01-31 2016-03-16 瓦克纳斯有限公司 用于提高免疫球蛋白a水平的方法
AU2013205589A1 (en) 2013-03-08 2014-09-25 Vaccinex, Inc. Anti-CXCL13 antibodies and associated epitope sequences
BR112015032690B1 (pt) 2013-06-25 2020-03-10 Vaccinex, Inc. Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
HRP20210096T1 (hr) 2015-03-31 2021-03-05 Medimmune Limited Novi oblik il33, mutirani oblici il33, protutijela, testovi i postupci njegove upotrebe
CN110325547B (zh) 2016-11-07 2023-12-26 德格克斯有限公司 新淀粉样蛋白β寡聚体特异性结合分子
ES2963046T3 (es) 2017-03-20 2024-03-25 Vaccinex Inc Tratamiento del cáncer con un anticuerpo contra la semaforina-4d combinado con un agente modulador epigenético
CA3061963A1 (en) 2017-05-05 2018-11-08 Vaccinex, Inc. Human anti-semaphorin 4d antibody
CN118370815A (zh) 2017-08-22 2024-07-23 渤健马萨诸塞州股份有限公司 含有抗β淀粉样蛋白抗体的药物组合物
WO2020198572A1 (en) 2019-03-28 2020-10-01 Vaccinex, Inc. Semaphorin-4d antagonists for use in cancer therapy
IL288779B2 (en) 2019-06-21 2025-11-01 Vaccinex Inc Combination therapy with semaphorin-4d blockade (sema4d) and dc1 therapy
AU2020322474A1 (en) 2019-08-01 2022-03-10 Vaccinex,Inc. Combined inhibition of semaphorin-4D and TGFβ and compositions therefor
CN117597360A (zh) 2020-06-25 2024-02-23 瓦西尼斯公司 脑信号蛋白-4d结合分子在rett综合征治疗中的应用
JP2024535403A (ja) 2021-09-27 2024-09-30 バクシネックス インコーポレーティッド 神経変性障害を処置するための抗セマフォリン４ｄ結合分子の使用に関する予測アウトカムプロファイリング
US20230331863A1 (en) 2022-02-13 2023-10-19 Vaccinex, Inc. Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease
WO2026030311A1 (en) 2024-07-29 2026-02-05 Vaccinex, Inc. Use of semaphorin-4d inhibitory molecules to treat cognitive impairment
WO2026080818A1 (en) 2024-10-10 2026-04-16 Vaccinex, Inc. Use of anti-semaphorin-4d inhibitory molecules in combination with flt3 ligand to inhibit tumor growth and metastasis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3942579A1 (de) * 1989-12-22 1991-06-27 Basf Ag Neue proteine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3942579A1 (de) * 1989-12-22 1991-06-27 Basf Ag Neue proteine

Also Published As

Publication number Publication date
FR2686087B1 (https=) 1994-04-22
WO1993014125A1 (fr) 1993-07-22

Similar Documents

Publication Publication Date Title
FR2686087A1 (fr) Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
Rock et al. TAP, a novel T cell-activating protein involved in the stimulation of MHC-restricted T lymphocytes.
US5521288A (en) CD28IG fusion protein
Bougeret et al. Increased surface expression of a newly identified 150-kDa dimer early after human T lymphocyte activation
US5601819A (en) Bispecific antibodies for selective immune regulation and for selective immune cell binding
CA2086325C (en) Ligand for cd28 receptor on b cells and methods
KR100238712B1 (ko) 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도
DK173382B1 (da) Hidtil ukendte heterokonjugater og bispecifikke antistoffer
Hérold et al. Activation signals are delivered through two distinct epitopes of CD100, a unique 150 kDa human lymphocyte surface structure previously defined by BB18 mAb
Spertini et al. Induction of human T cell proliferation by a monoclonal antibody to CD5
TW201000125A (en) A monoclonal antibody and a method thereof
EP0312542B1 (en) Gamma, delta t cell receptor and methods for detection
NZ193470A (en) Hybridoma for producing monoclonal antibody to human helper t cells;antibody;therapeutic and diagnostic compositions
US6830937B1 (en) Method for generating and identifying antibodies directed against a B7
US5185250A (en) Human γ, δT cell antigen receptor polypeptides and nucleic acids
AU664994B2 (en) Cell surface receptors homologous to coagulation factors V and VIII
IE50672B1 (en) Hybrid cell line for producing monoclonal antibody to human thymocyte antigen,antibody,method of preparation of this antibody,diagnostic and therapeutic uses and pharmaceutical compositions comprising this antibody
EP0501233A1 (en) Hybridomas and monoclonal antibodies that inhibit anti-CD3-stimulated T cell proliferation
US20030219446A1 (en) Ligand for CD28 receptor on B cells and methods
Harris et al. Identification of an evolutionarily conserved, function-associated molecule on human natural killer cells.
US5024940A (en) Nucleic acids encoding the delta chain of the T cell antigen receptor
US5124251A (en) CD3 ζ co-associated complex on CD16- NK cells
US4816404A (en) Late differentiation antigens associated with helper T lymphocyte function
KR101159140B1 (ko) Ｐ-셀렉틴 당단백질 리간드 1의 모듈레이터
Yssel et al. Distribution and functional analysis of a 120-to 130-kDa T-cell surface antigen

Legal Events

Date Code Title Description
ST Notification of lapse